Gyre Therapeutics, Inc.

GYRE Healthcare Biotechnology

In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.

6.08 0.32 −5.00%
Market cap
$678.6M
P/E
0.0×
Fwd P/E
−21.7×
Dividend yield
—
F-score
4/9
Altman Z
16.83
Beneish M
−2.02
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 86.43 141.20
Piotroski F-Score
2 4 4 — — — 8 4 5 4
Altman Z-Score
(6.50) (3.81) 8.65 — (1.65) (13.25) 26.41 25.08 23.76 16.83
P/S ratio
19.35 48.36 117.56 — 5.78 3.80 5.26 13.80 9.74 5.41
P/FCF ratio
0.00 0.00 0.00 — 0.00 0.00 98.87 87.15 0.00 0.00
Altman Z″-Score (non-manufacturers)
(12.82) (9.29) 24.45 — (5.67) (26.84) 9.96 (2.01) 5.15 8.71
P/Operating CF
(1.55) (7.79) (9.82) — (5.48) (1.58) 13.30 466.11 (373.33) (112.14)
Beneish M-Score
(3.91) — — — — — 9.51 (6.80) (1.20) (2.02)
P/B ratio
0.48 1.60 0.74 — 1.59 0.68 7.79 112.28 10.46 10.59
Price to Tangible BV
0.48 1.60 0.74 — 1.59 0.68 8.00 127.84 10.65 11.51
EV/Sales
(23.22) 16.39 (35.09) — 2.24 (1.87) 5.07 13.56 9.53 4.66
EV/EBITDA
0.46 0.00 0.78 — 0.00 0.16 52.54 0.00 56.80 38.79
EV/Operating CF
0.50 (0.84) 0.93 — (0.85) 0.16 50.84 59.40 (276.90) 537.99
EV/FCF
0.57 (0.84) 0.91 — (0.85) 0.16 95.36 85.58 (158.25) (615.37)
Quick Ratio
1.66 4.32 25.03 3.18 4.65 3.44 3.46 2.49 2.64 4.58
Current Ratio
1.71 4.48 25.83 3.32 5.03 3.63 4.06 2.85 3.32 5.60
Net Debt/EBITDA
0.86 1.51 3.57 1.35 1.39 0.53 (2.44) 0.51 (1.50) (3.74)
Debt/Assets
50.94% 12.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
1.21 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.01 0.03 0.00 0.00 0.22 0.10 1.46 1.13 0.87 0.80
Operating CF/Net income
1.09 0.78 0.95 0.79 0.98 0.95 4.64 (0.28) (0.30) 0.20
Capex/Depreciation
5.39 (0.13) (2.52) (0.44) (1.93) (2.89) (4.43) (7.11) (1.72) (0.75)
Interest Coverage
— — — (26.70) (102.26) (2,253.69) 17.14 — — —
ROE
(71.35%) (108.92%) (39.88%) (58.61%) (77.89%) (150.11%) 4.06% (215.71%) 21.51% 4.18%
ROA
(31.49%) (65.75%) (36.56%) (49.38%) (58.16%) (116.85%) 3.28% (92.34%) 9.99% 3.45%
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.23% (93.45%) 14.08% 7.99%
Return on Tangible Assets
(105.91%) (83.25%) (25.13%) (81.78%) (77.95%) (229.70%) 4.18% (153.70%) 17.48% 4.67%
Average Days of Receivables
28.36 0.00 0.00 0.00 57.73 90.43 61.15 52.92 85.52 98.02
Research and Development Expense of Revenue
2,895.99% 1,261.98% 357,900.00% 0.00% 252.89% 938.80% 16.31% 85.40% 11.37% 11.75%
Selling, General and Administrative Expense of Revenue
2,321.30% 981.63% 205,900.00% 0.00% 77.24% 258.42% 70.00% 66.83% 69.61% 73.75%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.01 0.04
Share Based Compensation of Revenue
159.15% 84.77% 43,433.33% 0.00% 17.31% 46.40% 13.07% 6.42% 0.79% 6.14%
Graham Net Nets
2.01 0.62 1.34 — 0.58 1.32 0.07 0.01 0.04 0.19
Graham Number
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 1.91 0.87
Earnings Yield
(218.29%) (65.38%) (33.57%) — (44.83%) (315.23%) (44.04%) (12.78%) 1.16% 0.71%
Free Cash Flow Yield
(212.07%) (40.55%) (32.68%) — (45.69%) (303.37%) 1.01% 1.15% (0.62%) (0.14%)
Revenue per Share
7.67 4.46 0.01 0.00 16.38 3.59 1.61 1.72 1.24 1.30
Operating CF per Share
(355.23) (87.30) (38.17) (54.47) (43.03) (40.98) 0.17 0.39 (0.04) 0.01
Capex per Share
40.31 (0.10) (0.50) (0.08) (0.21) (0.41) (0.08) (0.12) (0.03) (0.02)
Free Cash Flow per Share
(314.92) (87.40) (38.68) (54.55) (43.24) (41.39) 0.09 0.27 (0.07) (0.01)
Cash per Share
702.54 165.39 160.66 96.00 62.03 22.92 0.40 0.51 0.31 0.59
Shareholders Equity per Share
309.06 134.74 160.35 85.35 59.47 20.10 1.14 1.19 1.16 1.59
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
309.06 134.74 160.35 85.35 59.47 20.10 1.14 1.19 1.16 1.59
Free Cash Flow
(16.38) (19.96) (28.93) (43.68) (55.31) (84.59) 5.68 17.97 (6.37) (0.88)
Working Capital
15.56 30.37 119.19 67.17 71.71 37.31 37.41 37.17 45.27 84.08
Capital Expenditures
2.10 (0.02) (0.38) (0.06) (0.27) (0.84) (5.00) (7.92) (2.73) (1.89)
Net Current Asset Value
15.50 30.37 119.02 65.85 70.73 36.90 37.12 19.16 37.78 78.52
EV/EBIT
0.45 0.00 0.78 — 0.00 0.16 58.98 0.00 62.38 47.30
Capex to Sales
(5.25) 0.02 62.67 0.00 0.01 0.11 0.05 0.07 0.03 0.02
Price to Operating Income
0.00 0.00 0.00 — 0.00 0.00 61.15 0.00 63.70 54.91
Other line items
Depreciation/Fixed assets
0.88 0.63 0.39 0.48 0.32 0.30 0.06 0.05 0.07 0.11
Cash ROIC
(22.74%) (27.11%) (12.05%) (30.08%) (35.59%) (96.20%) 5.83% 16.05% (5.09%) (0.45%)
Accounts Receivable Turnover
1.53 0.00 0.00 0.00 2.29 2.86 10.79 6.76 5.13 4.16
Accounts Payable Turnover
0.00 0.00 0.00 0.05 1.79 1.20 1.47 19.44 16.78 46.69
Inventory Turnover
— — — 0.00 0.00 0.00 0.00 0.89 0.73 0.66
Average Days of Payables
0.00 0.00 0.00 10,697.50 236.26 317.47 9.29 27.95 10.15 8.36
Days of Inventory on Hand
— — — 0.00 0.00 0.00 466.21 337.05 595.52 685.45
Average Receivables
0.26 — — 7.52 9.16 2.57 9.48 16.79 20.62 28.04
Average Payables
0.89 0.79 1.00 2.76 5.11 6.18 3.27 0.24 0.23 0.12
Average Inventory
— — — — — — — 5.20 5.31 8.25
Average Assets
53.81 38.80 82.22 111.74 96.70 75.25 70.21 100.65 120.97 145.77
Average Common Equity
23.75 23.42 75.36 94.14 72.20 58.58 56.65 43.08 56.18 120.34

Fold the line items

Columns are period end dates